CD169 expression on monocytes as a marker for assessing type I interferon status in pediatric inflammatory diseases.

[1]  N. Unterwalder,et al.  SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies , 2021, medRxiv.

[2]  D. Teachey,et al.  Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response , 2021, Modern Pathology.

[3]  T. Haselhorst,et al.  The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease , 2021, International reviews of immunology.

[4]  D. San Segundo,et al.  Validation of a Quick Flow Cytometry-Based Assay for Acute Infection Based on CD64 and CD169 Expression. New Tools for Early Diagnosis in COVID-19 Pandemic , 2021, Frontiers in Medicine.

[5]  M. Picot,et al.  Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19 , 2020, medRxiv.

[6]  M. Noval Rivas,et al.  Kawasaki disease: pathophysiology and insights from mouse models , 2020, Nature Reviews Rheumatology.

[7]  P. Morange,et al.  Role of the interferons in CD64 and CD169 expressions in whole blood: Relevance in the balance between viral‐ or bacterial‐oriented immune responses , 2020, Immunity, inflammation and disease.

[8]  P. Morange,et al.  Clinical research assessment by flow cytometry of biomarkers for infectious stratification in an Emergency Department. , 2019, Biomarkers in Medicine.

[9]  J. Schultze,et al.  Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases , 2019, Front. Immunol..

[10]  Ji-Yih Chen,et al.  Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus , 2019, Cells.

[11]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.

[12]  F. Powrie,et al.  Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. , 2019, Immunity.

[13]  K. Brown,et al.  Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases. , 2019, Clinical and experimental rheumatology.

[14]  T. Niewold,et al.  Type I interferon in rheumatic diseases , 2018, Nature Reviews Rheumatology.

[15]  J. Todd,et al.  The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus , 2018, bioRxiv.

[16]  R. de Groot,et al.  Siglec‐1 inhibits RSV‐induced interferon gamma production by adult T cells in contrast to newborn T cells , 2018, European journal of immunology.

[17]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[18]  B. McCrindle,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association , 2017, Circulation.

[19]  Andreas Radbruch,et al.  SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome , 2016, RMD Open.

[20]  M. Netea,et al.  IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections , 2016, PLoS pathogens.

[21]  C. Rice,et al.  Interferon-stimulated genes: a complex web of host defenses. , 2014, Annual review of immunology.

[22]  R. Zhong,et al.  Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis. , 2014, Rheumatology.

[23]  A. Vanderver,et al.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study , 2013, The Lancet Neurology.

[24]  John H Livingston,et al.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature , 2012, Nature Genetics.

[25]  Y. Crow.  Type I interferonopathies: a novel set of inborn errors of immunity , 2011, Annals of the New York Academy of Sciences.

[26]  Thomas Häupl,et al.  Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[27]  R. Lafyatis,et al.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. , 2007, Arthritis and rheumatism.